Investors seeking direct access to management teams in the life sciences sector will have an opportunity on September 17, 2026, when seven companies present live at the Life Sciences Virtual Investor Forum. The online event, hosted by Virtual Investor Conferences and marketed by B2i Digital, Inc., will feature 30-minute presentations followed by audience Q&A, with replays available on the B2i Digital and OTC Markets YouTube channels.
The lineup spans a diverse range of therapeutic areas and technologies, from photothermal cancer therapy built on gold nanorods to cannabinoid-based formulations in development for rheumatoid arthritis, chronic lung inflammation and autoimmune disease. Precision drug delivery technologies aimed at targets including behind the blood-brain barrier will also be presented, alongside a new class of antibiotics targeting priority pathogens and a humanized monoclonal antibody being studied in solid-tumor oncology. Additionally, a pipeline of Focal Adhesion Kinase inhibitors for cancer and fibrosis and FDA-cleared four-dimensional respiratory imaging round out the agenda.
Presenting companies as of September 11, 2026, include Sona Nanotech Inc., Raphael Pharmaceutical, Amplia Therapeutics Ltd., Adaptin Bio, Inc., Acurx Pharmaceuticals, Inc., CytoDyn Inc., and 4DMedical Ltd., each scheduled for a 30-minute session beginning at 11:00 AM ET. The event details and presenting company profiles are available at https://b2idigital.com/sept-17-life-sciences-virtual-investor-forum, and registration can be completed at https://www.virtualinvestorconferences.com/wcc/eh/4814904/category/150412/september-17th-life-sciences-virtual-investor-forum?utm_source=b2i&utm_medium=marketing&utm_campaign=0917SeptLifeScienceVIC.
David Shapiro, Chief Executive Officer of B2i Digital, Inc., emphasized the value of live interaction. “Reading company filings is a great cure for insomnia, but if you want to stay awake and hear it directly from management, these conferences are the best way to get a real feel for the company,” Shapiro said. “My favorite part is the Q&A and hearing how they handle the impromptu questions that are really on your mind.”
The forum’s significance lies in its timing and format. As investors increasingly seek transparency and direct engagement, virtual conferences offer a platform for companies to articulate their progress and for investors to probe management on critical issues. With sectors like oncology, fibrosis, and antibiotics facing evolving challenges and opportunities, the event provides a snapshot of innovation across the life sciences landscape. The inclusion of early-stage and clinical-stage companies suggests a focus on emerging therapies that could address unmet medical needs.
B2i Digital, as the Official Marketing Partner, brings its extensive media network and investor community to amplify the event. Virtual Investor Conferences, an OTC Markets Group Inc. property, regularly features public companies from major exchanges worldwide. The September 17 forum underscores the growing trend of virtual investor engagement, particularly in the life sciences where scientific complexity demands direct dialogue. For investors, the event offers a chance to assess potential opportunities and risks firsthand, making it a noteworthy date on the calendar.
